Search Results
Your search for ,ouT matches 5632 pages
Showing 1 - 50AML: All-Oral Regimen Safe and Eases Treatment Administration Burden
An all-oral treatment regimen led to complete responses in almost half of all patients with newly diagnosed acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy, according to findings from the phase I/II ASCERTAIN V trial published in The New England Journal of Medicine....
Online Patient Resources About AI and Cancer Found Lacking
Online resources for patients and the general public focused on artificial intelligence (AI) and its uses in cancer research and cancer care were found lacking in a cross-sectional analysis presented at the 2026 ASCO Annual Meeting (Abstract 9000). The study highlighted that the existing webpages...
After the Founder: What a Cervical Cancer Program in Haiti Teaches About Sustaining Prevention
In 2016, The ASCO Post published an article titled “An Oncologist Battles a Preventable Epidemic: Cancer of the Cervix,” highlighting the work of Robert D. Hilgers, MD—now deceased—and the Women’s Global Cancer Alliance (WGCA) in building a cervical cancer screening and prevention program in...
Radiotherapy for Prostate Cancer: HERMES Trial Compares Two and Five Fractions
Two larger doses of radiotherapy for prostate cancer caused no additional side effects compared to the standard five doses of radiotherapy, according to results from the HERMES trial presented at the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026). Experts say the...
Better Together: The Case for True Physician-AP Partnership in Oncology
At 8 am, the infusion chairs are already full. The oncologist is in a room seeing a new patient consult, the pharmacist is adjusting doses based on new lab values, and the advanced practitioner (AP) is sitting with a patient—reviewing symptoms, discussing how to manage treatment side effects, and ...
I Have Advanced-Stage Lung Cancer. I Refuse to Be a Victim of the Disease
I remember thinking on the day I turned 60, May 10, 2021, “This is going to be the best year of my life.” I couldn’t have been more wrong. Within weeks of feeling that swell of optimism about my future, I began experiencing a series of odd, and, seemingly unrelated symptoms leading to my eventual...
A Timely Compendium for the Era of Precision Oncology
The pace at which precision oncology has evolved over the past 2 decades, from the early promise of the Human Genome Project to the clinical reality of CAR T-cell therapy, antibody drug conjugates, and AI-assisted decision support, has made it increasingly difficult for even the most engaged...
Using Artificial Intelligence to Prescribe Cancer Drugs and Perform Other Tasks
In a recent article in The ASCO Post, we discussed increasing use of artificial intelligence (AI) in oncology and how physician-complementing AI can empower oncologists to be even better at what they do.1The reason AI is needed is that increasingly many variables need to be considered in cancer...
Facing a Year Ahead of Unprecedented Opportunities—and Challenges
This year has marked unprecedented progress against cancer—as well as challenges. According to findings in the American Cancer Society’s Cancer Statistics, 2026 report, the 5-year relative survival rate for all cancers combined has reached a milestone of 70% for individuals diagnosed between 2015...
Early Myocarditis After Immune Checkpoint Inhibitors Signals Elevated Mortality Risk
Early onset of immune checkpoint inhibitor (ICI)–related myocarditis is associated with increased mortality risk, as is the presence of concurrent major adverse cardiac events, according to results presented in a poster and at a press briefing during the 2026 American Association for Cancer...
Head-to-Head on Headspace: Cognitive Effects of Darolutamide vs Enzalutamide in Advanced Prostate Cancer
Patients with advanced prostate cancer treated with darolutamide experienced significantly less objectively assessed cognitive decline over 24 weeks than those receiving enzalutamide, according to results from the prospective, randomized open-label phase II ARACOG (AFT-47) trial to be presented at...
Case 3: Relapsed/Refractory Follicular Lymphoma in the Third Line and Beyond
This is Part 3 of Relapsed/Refractory Follicular Lymphoma: Choosing the Right Regimen for the Right Patient, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Loretta Nastoupil, Carla Casulo, and Kami Maddocks discuss treatment...
Case 1: Early Relapsed Follicular Lymphoma
This is Part 1 of Relapsed/Refractory Follicular Lymphoma: Choosing the Right Regimen for the Right Patient, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Loretta Nastoupil, Carla Casulo, and Kami Maddocks discuss the...
AI Avatar–Based Education Leads to Improved Patient Understanding of Radiation Treatment Plans
A new study has shown that AI avatar–based digital patient engagement prior to in-person radiation treatment consultations may enable patients to feel more knowledgeable and less stressed than patients who did not engage with an AI avatar, according to findings presented during the Congress of the...
ASCENDE-RT 15-Year Update Shows No Overall Survival Benefit, With ‘Borderline’ Signal for Fewer Deaths
Fifteen-year results from the phase III ASCENDE-RT trial in patients with intermediate- and high-risk localized prostate cancer receiving androgen-deprivation therapy (ADT) and pelvic external-beam radiotherapy (EBRT) show no significant overall survival advantage with a prostate brachytherapy...
Study Shows Potential Missing Patient Information in SEER Database
A significant number of patients with cancer—particularly those with more advanced disease who are more likely to receive care at community hospitals, safety net hospitals, and rural medical centers—may have incomplete case information in the Surveillance, Epidemiology, and End Results (SEER)...
Study Finds Methylphenidate-Type Psychostimulants May Reduce Cancer-Related Fatigue
A new meta-analysis published by Costa et al in JNCCN—Journal of the National Comprehensive Cancer Network provides updated evidence that methylphenidate-type psychostimulants—a class of medication that increases dopamine and norepinephrine availability in the brain—can provide meaningful relief...
Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC
In the final analysis of the phase III EORTC 1333/PEACE-3 trial, with a median follow-up of 58 months, the addition of radium-223 to the androgen receptor inhibitor enzalutamide significantly prolonged overall survival in patients with bone-dominant metastatic castration-resistant prostate cancer...
Noninvasive Urine Test May Provide Grade Group Information in Patients With Prostate Cancer
A new urine test performed better than prostate specific antigen (PSA)-based testing and magnetic resonance imaging (MRI) for monitoring patients with low-risk prostate cancer on active surveillance. Use of the test to determine the need for repeat “monitoring” biopsies would have avoided up to 64% ...
I’m Young and Have Advanced Neuroendocrine Carcinoma of the Rectum
Eight years ago, I was 33 years old, and my main health concern was a diagnosis of ankylosing spondylitis, a form of arthritis that causes stiff, painful joints in the spine. Having a chronic disease made me pay close attention to any changes in my health, so when I noticed blood in my stool, I...
Can Physical Activity Reduce Cancer-Related Fatigue?
Greater physical activity—particularly walking—may reduce fatigue and improve quality of life in patients with colorectal cancer, with stronger associations observed in nonmetastatic disease. These findings were demonstrated in a longitudinal analysis of the ColoCare Study population presented by...
LLM Tool Significantly Reduces Participant Screening Burdens, Improves Enrollment for Phase III Trial in Polycythemia Vera
Synapsis AI, a medically trained, large language model (LLM)–based end-to-end system, reduced the time and effort needed to screen for eligible patients to participate in a randomized, interventional phase III clinical trial in patients with polycythemia vera (PV). Use of Synapsis AI also led to...
Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma
At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib improved progression-free survival, produced a higher objective response rate, and showed a trend...
Can Pesticide Exposure Increase Early-Onset Colorectal Cancer Risk?
A new study has identified for the first time the exposome footprint—the set of environmental and lifestyle exposures—for colorectal cancer occurring in patients younger than age 50 through epigenetic signatures. By comparatively analyzing DNA methylation patterns in patients under and over 50, the ...
AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS
Monitoring for relapse with an artificial intelligence (AI)-powered peripheral blood-based tool called AlloHeme demonstrated greater sensitivity in predicting relapse after hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) than ...
Global Review Shows Impact of Exposure to Air Pollution on Cancer Risk and Mortality
Long-term exposure to air pollution significantly increases both the risk of developing cancer and the likelihood of dying from the disease, according to a new global evidence report released by the Union for International Cancer Control (UICC), titled Clean air in cancer control: An overview of...
RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer
The treatment landscape for advanced pancreatic cancer is shifting. The common RAS mutation is now targetable and the race for the most effective inhibitor is heating up. In mid-April, Revolution Medicines announced positive results from its phase III RASolute 302 clinical trial of daraxonrasib, an ...
Early-Onset Lung Cancer May Be Connected to Pesticide Contaminants
Dietary patterns in young patients with lung cancer suggest that many have higher dietary quality scores than average U.S. reference values, according to results from a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 5039). The researchers...
ACP Issues Controversial New Breast Cancer Screening Guidelines
New guidance from the American College of Physicians (ACP) says all average-risk females between ages 50 to 74 should receive biennial screening mammography for breast cancer, and that females between the ages of 40 and 49 should discuss with their doctor their risk for breast cancer and the...
Update to Patient–Clinician Communication Guideline Provides Recommendations on Telehealth, Boundary-Setting
ASCO has updated its guideline on patient–clinician communication, providing recommendations on a range of best practices for explaining treatment options and goals of care, conversing with patients’ support networks, communicating among care team members, and setting boundaries.1 The update to the ...
Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in BRCA/ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Updated results from the phase II BRCAAway trial showed that first-line treatment with abiraterone and prednisone plus olaparib resulted in a median overall survival of more than 5 years in patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 and/or ATM alterations.1...
What Is the Optimal Setting for T-DXd in Early Breast Cancer? Experts Debate
Trastuzumab deruxtecan (T-DXd) has claimed a large share of the HER2-positive breast cancer landscape, even finding room among tumors previously thought to be HER2-negative. The DESTINY series of trials are international studies investigating T-DXd as a potential treatment option for eligible...
Early-Onset ICI-Related Myocarditis Linked to Increased Mortality
Early-onset of immune checkpoint inhibitor (ICI)–related myocarditis was associated with an increased risk for myocarditis fatality, according to the results of a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 5212). The researchers suggested...
Elisrasib Demonstrates High Disease Control Rate in KRAS G12C–Mutant NSCLC
Elisrasib, a next-generation KRAS G12C inhibitor, demonstrated disease control in a majority of patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), whether exposed to a prior KRAS G12C inhibitor or not, according to findings from an ongoing phase I/II clinical trial presented at the ...
AYA Cancer Survivors and Risk for Earlier Subsequent Primary Neoplasms
About one in six survivors of an adolescent and young adult cancer will develop a subsequent primary neoplasm within 30 years of their original diagnosis, according to the results of a population-based study published in the Canadian Medical Association Journal. “When combined with the relatively...
Is Standard of Care Optimal for the Individual Patient?
I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded his facial nerve. Several weeks ago, when the PA’s fingers moved over the mass visibly protruding...
POSITIVE Trial Update: Oncologic Outcomes Maintained After Pausing Endocrine Therapy for Pregnancy
For years, the question of pregnancy after, or during treatment for, hormone receptor–positive breast cancer placed patients and their oncologists in an uncomfortable position. Endocrine therapy, prescribed for 5 years and increasingly for 10 years or longer in high-risk patients, is both a...
How Cannabis Use May Be Accelerating Breast and Testicular Cancer Rates in AYAs
As the data continue to show, the incidence of breast, testis, and other cancers are on the rise in adolescent and young adults (AYAs) between the ages of 15 and 39, with increases of 30% over the last 4 decades.1 And while potential explanations for this rapid increase have included obesity,...
Damaging Missense Variants in Innate Immunity Genes Linked to Earlier Breast Cancer Onset in BRCA1 Carriers
Damaging variants in genes involved in a rapid immune response (innate immunity) are significantly linked to earlier breast cancer onset in carriers of the BRCA1 genetic mutation, according to preliminary findings published by Shemesh et al in the Journal of Medical Genetics. The strongest...
NCCN 2026 Annual Conference Prepares Cancer Care Providers Worldwide for Healing the Whole Patient
The National Comprehensive Cancer Network® (NCCN®) brought together more than a thousand oncology professionals at the NCCN 2026 Annual Conference in Orlando, with hundreds more joining virtually. This year’s event featured educational sessions on breakthroughs in cancer prevention and treatment,...
Surgery Still Safe, Beneficial For Many Octogenarian Patients With NSCLC
Surgical treatment was found to be safe and demonstrate long-term quality-of-life benefits for carefully selected octogenarians with early-stage non–small cell lung cancer (NSCLC), according to findings from a prospective cohort study published in The Lancet Regional Health: Americas. “As our...
Early Results From a Trial of Active Surveillance for Low-Risk DCIS are ‘Reassuring,’ Say Researchers
Researchers leading the LORD trial of active surveillance for ductal carcinoma in situ (DCIS) described early results as “reassuring” in a presentation to the 15th European Breast Cancer Conference (EBCC15) in Barcelona (Abstract 2LBA). People diagnosed with DCIS have abnormal cells inside the milk ...
Molecular Test Doubles Detection of Bile Duct Cancer
When patients develop a narrowing or blockage in the bile ducts, physicians must determine whether the cause is cancer or a benign condition. The location of these blockages adds challenges to the diagnosis, and this uncertainty can delay treatment decisions for patients in the event they have this ...
AI Use in Cancer Diagnosis, Prognosis, and Treatment: Are We There Yet?
The promise of artificial intelligence (AI) technologies to provide highly personalized oncology care for patients and improve outcomes has been decades in the making. In a 1987 editorial in The New England Journal of Medicine, pioneering nephrologist and health economist William B. Schwartz, MD,...
Breast Cancer Recurrence Remains Low—Even After 10 Years—With Radiotherapy Tailored to Patient’s Individual Risk
The chances of breast cancer recurring remain low when patients are treated with radiotherapy that is tailored to their individual risk following chemotherapy and surgery. These are the findings of a 10-year Dutch study (RAPCHEM; BOOG 2010-03) presented at the 15th European Breast Cancer Conference ...
Breast Reconstruction Using Polyurethane-Coated Implants May Reduce the Risk of Capsular Contracture, Additional Surgery
Women who are treated with mastectomy for breast cancer often choose to have breast reconstructive surgery using an implant. But hard, painful scar tissue can form around the implant, especially when women also receive radiotherapy as part of their treatment. Findings from the OPBC-09 PRExRT study, ...
ASH 2025: Myelofibrosis Roundup
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
In Celebration of a Decades-Long Journey of Discovery and Innovation
On October 1, 2025, Benjamin L. Ebert, MD, PhD, celebrated the 1-year anniversary of being named President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute in Boston. He also holds the titles of Director of Dana-Farber/Harvard Cancer Center, the Richard and Susan Smith Professor of ...
How AI Is Already Having a Significant Impact on Cancer Care
Three education sessions presented during the 2025 ASCO Annual Meeting showcased how artificial intelligence (AI) is quickly transforming cancer care from clinical trial planning and ambient scribes transcribing physician-patient conversations to therapeutic decision-making. The meeting also...
Myelofibrosis: Treatment Landscape Is Poised for Change
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
